Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have received a consensus rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.80.

Separately, Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $8.94 on Wednesday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of 149.00 and a beta of 0.62. The firm’s 50-day moving average price is $6.71 and its two-hundred day moving average price is $6.65. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a 1-year low of $4.66 and a 1-year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, equities analysts predict that Xeris Biopharma will post 0.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Xeris Biopharma news, Director Dawn Halkuff sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $121,800.00. Following the completion of the sale, the director owned 95,000 shares in the company, valued at approximately $578,550. This trade represents a 17.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the transaction, the director directly owned 126,500 shares of the company’s stock, valued at approximately $770,385. This represents a 11.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 251,500 shares of company stock valued at $1,846,457 over the last three months. Company insiders own 4.35% of the company’s stock.

Institutional Trading of Xeris Biopharma

Hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers increased its holdings in shares of Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after purchasing an additional 1,735 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares in the last quarter. Royal Bank of Canada boosted its position in Xeris Biopharma by 6.5% in the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after buying an additional 2,351 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in Xeris Biopharma by 17.7% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after buying an additional 2,420 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its stake in shares of Xeris Biopharma by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after buying an additional 2,494 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.